Trial | NCT01404364  Report issue

Official Title

Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    36
The purpose of this study is to evaluate the efficacy of intravitreal triamcinolone and retrobulbar chlorpromazine as alternatives in the management of ocular pain in blind eyes.
The management of chronic eye pain is a constant challenge to ophthalmology. Treatment varies with the intensity of pain, and topical eye drops and contact lens therapy are effective in many patients. In refractory cases, and without vision, surgical removal of the eye through enucleation is considered classical therapy. As less invasive alternatives we have cyclodestruction and neurolytic drug injection in order to promote analgesia for a prolonged period.

The purpose of this study is to evaluate the efficacy of intravitreal triamcinolone and retrobulbar chlorpromazine as alternatives in the management of This is a prospective study of patients with blind painful eyes not responsive to topical treatment and with no indication for evisceration seen at the Department of Ophthalmology, Hospital Governador Celso Ramos (HGCR) in 2010.
Study Started
Jan 31
2010
Primary Completion
Dec 31
2010
Study Completion
Dec 31
2010
Last Update
Jul 28
2011
Estimate

Drug Triamcinolone

0,3mL intravitreal injection of Triamcinolone, single dose

Drug Chlorpromazine

2,5mL Chlorpromazine retrobulbar injection, single dose

  • Other names: Amplictil

Intravitreal Triamcinolone Active Comparator

Patients with phthisis bulbi received 0,3ml intravitreal triamcinolone injection

Retrobulbar Chlorpromazine Active Comparator

Patients with refractory glaucoma and blind painful eye were submitted to 2,5mL Chlorpromazine retrobulbar injection

Criteria 

Inclusion Criteria:

patients treated in the period at HGCR who wanted to be part of the protocol by signing the consent form

Exclusion Criteria:

patients whose follow-up period was less than three months
No Results Posted